FOXO4-DRI is studied in research on cellular energy metabolism and longevity. In senescent cells, the transcription factor FOXO4 sequesters p53, blocking its apoptotic function. FOXO4-DRI competes with endogenous FOXO4 for p53 binding, releasing p53 and selectively triggering apoptosis in senescent cells while largely sparing healthy cells.
A key candidate in senescence and aging research: in the original study, FOXO4-DRI improved fitness, fur density, and kidney function in aged mice, and accelerated recovery from chemotherapy.
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Research on longevity and energy metabolism is primarily supported by preclinical data.
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
We reply personally – via email or Telegram.